ALLSTIM: Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia

Feasibility and Efficacy of Transcranial Direct Current Stimulation (tDCS) and Cognitive Training for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia

Categories:

Long-term Effects

Phase I/II

Diseases Treated:

Childhood acute lymphoblastic leukemia

Eligibility Overview:

 

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant is currently enrolled in SJLIFE.
  • Participant is greater than or equal to eighteen (18) years of age at time of evaluation.
  • Participant is not currently on stimulants or other medications intended to treat cognitive impairment.
  • Participant has full scale IQ greater than seventy-nine (79).
     

 

Description

This study will enroll participants who are long-term survivors of childhood Acute Lymphoblastic Leukemia (ALL). Treatment for ALL may or may not cause long-term cognitive problems, including ability to think in a flexible and fluent way. These problems can cause difficulty in daily life. This study will evaluate whether a form of non-invasive brain stimulation called Transcranial Direct Current Stimulation (tDCS) is a potentially useful way to improve cognitive abilities. The study will use tDCS to apply a low electrical current to the scalp in the area of the brain that controls fluent and flexible thinking which may make that area of the brain work better for a short period of time.

Objectives

  • To evaluate the feasibility of a home-based intervention using tDCS and cognitive training in adult survivors of childhood ALL participating in the SJLIFE study.
  • To estimate the efficacy of a tDCS intervention paired with cognitive training.
  • To evaluate short-term effects of tDCS on measures of executive function among adult survivors of childhood ALL participating in the SJLIFE study.

Eligibility criteria (among others)

  • Participant is currently enrolled in SJLIFE.
  • Participant is greater than or equal to eighteen (18) years of age at time of evaluation.
  • Participant has Wi-Fi internet access at home.
  • Participant is not currently on stimulants or other medications intended to treat cognitive impairment.
  • Participant has full scale IQ greater than seventy-nine (79).

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children’s Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Principal Investigator

Kevin Krull, PhD

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334

Referring or consulting clinicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: referralinfo@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.